During the last three months, 8 analysts shared their evaluations of Health Catalyst (NASDAQ:HCAT), revealing diverse outlooks from bullish to bearish.

The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.

Analysts have recently evaluated Health Catalyst and provided 12-month price targets. The average target is $9.56, accompanied by a high estimate of $12.00 and a low estimate of $7.00. This upward trend is apparent, with the current average reflecting a 2.14% increase from the previous average price target of $9.36.

Analyzing Analyst Ratings: A Detailed Breakdown

The perception of Health Catalyst by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.

Key Insights:

Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Health Catalyst's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.

Stay up to date on Health Catalyst analyst ratings.

If you are interested in following small-cap stock news and performance you can start by tracking it here.

Get to Know Health Catalyst Better

Health Catalyst's Economic Impact: An Analysis

Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.

Revenue Growth: Over the 3 months period, Health Catalyst showcased positive performance, achieving a revenue growth rate of 3.5% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.

Net Margin: Health Catalyst's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -19.29% net margin, the company effectively manages costs and achieves strong profitability.

Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of -4.14%, the company showcases effective utilization of equity capital.

Return on Assets (ROA): Health Catalyst's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of -1.96%, the company showcases efficient use of assets and strong financial health.

Debt Management: With a below-average debt-to-equity ratio of 1.03, Health Catalyst adopts a prudent financial strategy, indicating a balanced approach to debt management.

What Are Analyst Ratings?

Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter.

Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.

Breaking: Wall Street's Next Big Mover

Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. Click here for urgent details.

This article was generated by Benzinga's automated content engine and reviewed by an editor.